Study identifier:D8750C00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:2025-523379-41
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)
Obesity or Overweight
Phase 3
No
AZD6234, Placebo
All
2500
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2026 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD6234 Dose 1 AZD6234 Dose 1 | Drug: AZD6234 IMP injected subcutaneously, once a week. Unit dose strength as per CSP. |
| Experimental: AZD6234 Dose 2 AZD6234 Dose 2 | Drug: AZD6234 IMP injected subcutaneously, once a week. Unit dose strength as per CSP. |
| Placebo Comparator: Placebo Matching placebo | Drug: Placebo Placebo matching IMP dose injected subcutaneously, once a week. |